21801-86-5

Basic information

• Product Name: 2-IMIDAZO[1,2-A]PYRIDIN-3-YLACETAMIDE
• Synonyms: 2-IMIDAZO[1,2-A]PYRIDIN-3-YLACETAMIDE;Imidazo(1,2-a)pyridine-3-acetamide;3-(Carbamoylmethyl)imidazo(1,2-A)pyridine;Brn 1568679;Imidazo(1,2-A)pyridine, 3-(carbamoylmethyl)-
• CAS NO: 21801-86-5
• Molecular Formula: C9H9N3O
• Molecular Weight: 175.18726
• Mol File: 21801-86-5.mol

Chemical Properties

• Appearance: /
• Density: 1.34 g/cm³
• Refractive Index: 1.672
• PKA: 15.52±0.40(Predicted)
• CAS DataBase Reference: 2-IMIDAZO[1,2-A]PYRIDIN-3-YLACETAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-IMIDAZO[1,2-A]PYRIDIN-3-YLACETAMIDE(21801-86-5)
• EPA Substance Registry System: 2-IMIDAZO[1,2-A]PYRIDIN-3-YLACETAMIDE(21801-86-5)

Safety Data

• Hazardous Substances Data: 21801-86-5(Hazardous Substances Data)

Usage

Uses

As the specific uses and effects of 2-IMIDAZO[1,2-A]PYRIDIN-3-YLACETAMIDE are still under research, the following applications are based on its potential and the general properties of similar compounds:
Used in Pharmaceutical Industry:
2-IMIDAZO[1,2-A]PYRIDIN-3-YLACETAMIDE is used as a potential therapeutic agent for the development of new drugs, given its unique structure that may exhibit biological activity against certain diseases or medical conditions.
Used in Medicinal Chemistry Research:
2-IMIDAZO[1,2-A]PYRIDIN-3-YLACETAMIDE serves as a subject of study in medicinal chemistry, where its properties and interactions with biological targets are being explored to understand its potential as a lead compound for drug discovery.

InChI:InChI=1/C9H9N3O/c10-8(13)5-7-6-11-9-3-1-2-4-12(7)9/h1-4,6H,5H2,(H2,10,13)

Upstream product

• 101820-69-3 imidazo[1,2-α]pyridin-3-yl-acetic acid ethyl ester 
• 504-29-0 2-aminopyridine 
• 109-09-1 2-chloropyridine 
• 109-04-6 2-bromo-pyridine 
• 142-08-5 2-hydroxypyridin 

Downstream Products

• 603281-60-3 LY2090314 
• 603288-22-8 LY2090314 
• 17745-04-9 imidazo<1,2-a>pyridin-3-acetic acid 

Relevant articles and documents

Preparation method of minodronic acid key intermediate

The invention belongs to the technical field of drug synthesis, and provides a preparation method of a minodronic acid key intermediate. The method comprises the following steps: reacting ethyl 4-chloroacetoacetate with an ammonia organic solution to obtain a compound V, and reacting the compound V with a compound IV under the catalysis of a [Cu] catalyst to obtain a compound III imidazo[1,2-a]pyridine-3-acetamide; and hydrolyzing the compound III with concentrated hydrochloric acid to obtain a compound II imidazo[1,2-a]pyridine-3-acetic acid. The method has the advantages that the reaction conditions are simple, the raw material utilization degree is high, the yield is high, the purity is high, the pollution to the environment is small, and the method is suitable for industrial production.

METHODS FOR HAIR FOLLICLE STEM CELL PROLIFERATION

The present invention relates to compositions of minoxidil and Sonic Hedgehog (Shh) pathway activators and optionally, Wnt agonists and methods of using them to induce self-renewal of hair follicle stem cells, including inducing the hair follicle stem cells to proliferate while maintaining, in the daughter cells, the capacity to differentiate into hair follicle epithelial cells.

Practical and scalable preparation of Minodronic acid and Zolpidem from 2-chloroimidazole[1,2-a]pyridines

Practical and scalable procedures for Minodronic acid and Zolpidem are developed with short reaction sequences from 2-aminopyridines and maleic anhydride, respectively. The new procedures avoid column chromatography for the purification in all synthetic steps. Key aspects of this development involve reductive hydrodechlorination and Suzuki coupling reaction of 2-chloroimidazole[1,2-a]pyridines, and their application towards synthesis of the two drugs is also addressed.

1,5-DIHYDRO-2H-PYRROL-2-ONE COMPOUNDS AND METHODS OF USING SAME

The present invention relates to 1,5-dihydro-2H-pyrrol-2-one compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells, including inducing the stem/progenitor cells to proliferate while maintaining, in the daughter cells, the capacity to differentiate into tissue cells.

1H-PYRROLE-2,5-DIONE COMPOUNDS AND METHODS OF USING THEM TO INDUCE SELF-RENEWAL OF STEM/PROGENITOR SUPPORTING CELLS

The present invention relates to 1H-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells, including inducing the stem/progenitor cells to proliferate while maintaining, in the daughter cells, the capacity to differentiate into tissue cells.

METHODS FOR HAIR FOLLICLE STEM CELL PROLIFERATION

The present invention relates to compositions of Sonic Hedgehog (Shh) pathway activators and Wnt agonists and methods of using them to induce self-renewal of hair follicle stem cells, including inducing the hair follicle stem cells to proliferate while maintaining, in the daughter cells, the capacity to differentiate into hair follicle epithelial cells.

POTENTIATION OF CANCER CHEMOTHERAPY

An improved method for treating gastric cancer, ovarian cancer, non-small cell lung cancer, or colorectal cancer in a patient is described, as well as pharmaceutical compositions useful for the method and a process for preparing said compositions.

HEMATOPOIETIC NEOPLASM CHEMOTHERAPY

A method and medicament for treating mixed lineage leukemia; translocated mixed lineage leukemia; translocated mixed lineage leukemia based acute myelogenous leukemia; translocated mixed lineage leukemia based acute lymphoid leukemia; a non-MLL based chronic myeloproliferative disorder, or non-MLL based acute lymphoid leukemia is provided.

The development of potent and selective bisarylmaleimide GSK3 inhibitors

Many 3-aryl-4-(1,2,3,4-tetrahydro[1,4]diazepino[6,7,1-hi]indol-7-yl) maleimides exhibit potent GSK3 inhibitory activity (50), although few show significant selectivity (>100 ×) versus CDK2, CDK4, or PKCβII. However, combining 3-(imidazo[1,2-a]pyridin-3-yl), 3-(pyrazolo[1,5-a]pyridin-3-yl) or aza-analogs with a 4-(2-acyl-(1,2,3,4- tetrahydro[1,4]diazepino[6,7,1-hi]indol -7-yl)) group on the maleimide resulted in very potent inhibitors of GSK3 (≤5 nM) with >160 to >10,000-fold selectivity versus CDK2/4 and PKCβII. These compounds also inhibited tau phosphorylation in cells and were effective in lowering plasma glucose in a rat model of type 2 diabetes (ZDF rat).

Substituted 3-imidazo[1,2-a]pyridin-3-yl-4-(1,2,3,4-tetrahydro-[1,4] diazepino-[6,7,1-hi]indol-7-yl)pyrrole-2,5-diones as highly selective and potent inhibitors of glycogen synthase kinase-3

Glycogen synthase kinase-3 (GSK3) is involved in signaling from the insulin receptor. Inhibitors of GSK3 are expected to effect lowering of plasma glucose similar to insulin, making GSK3 an attractive target for the treatment of type 2 diabetes. Herein we report the discovery of a series of potent and selective GSK3 inhibitors. Compounds 7-12 show oral activity in an in vivo model of type II diabetes, and 9 and 12 have desirable PK properties.